Characteristics of COVID-19 Vaccines Available in Canada

 SHA has a Vaccine Comparison table available in General Vaccine Information.

Pfizer-BioNTech 
Comirnaty™ 
5-11 Years

Pfizer-BioNTech 
Comirnaty™ 
≥12 Years

Moderna Spikevax™ 

AstraZeneca Vaxzevria™  

Janssen 
(Johnson & Johnson)

Vaccine Technology mRNA mRNA mRNA Viral vector 
ChAdOx1-S
(recombinant)
Viral vector
Ad26.COV2.S (recombinant)
Packaging

Multi-dose preservative-free vials containing 10 doses

Cartons of 10 or 195 vials

Orange cap; orange border on vial

Multi-dose preservative-free vials containing 6a doses

Cartons of 25 and 195 vials

Purple cap; purple border on vial (may not yet be on existing inventory)

Multi-dose preservative-free vials containing maximum 20 doses depending on volume of dose being administered

Cartons of 10 vials

US-labelled product available in vials containing 14 (maximum 15) 0.5 mL dosesb

Multi-dose preservative-free available in:
8 dose vial (4 ml) 
10 dose vial (5 ml)

Multi-dose preservative-free vial containing 5 doses

Cartons of 10 vials
Storage/Stability
Stability in Freezer

Store at -90°C to -60°C (ultrafreezer) for up to 6 months from date on label.

Date on label is the date of manufacture.

Do not store at -25°C to -15°C.

Store at -90°C to -60°Cc (ultrafreezer) until the expiry date printed on the label.d

Store and/or transport at -25°C to -15°C for up to 2 weeks.e 

Store at -25°C to -15°C (freezer) until the expiry date printed on the label.f Do not freeze. May be stored and/or transported at -25°C to -15°C (freezer) until expiry date printed on vial and carton after “EXP”.
Thawing

Thaw undiluted product in fridge (takes up to 4 hours).
or
Thaw undiluted product at room temperature (takes ~30 minutes).

Do not refreeze thawed vials.

Thaw undiluted product in fridge (takes up to 3 hours).
or
Thaw undiluted product at room temperature (takes ~30 minutes).

Do not refreeze thawed vials.

Thaw in fridge (takes 2.5 hours), let stand at room temperature for 15 minutes before administration.
or
Thaw at room temperature (takes 1 hour).

Do not refreeze thawed vials.

Not required 

Do not freeze.

Thaw over night in fridge
or
Thaw at room temperature up to 25°C (single vial takes ~1 hour; carton of 10 vials takes ~4 hours).

Do not refreeze thawed vials. 

Stability in Fridge (2°C to 8°C)

Undiluted product: up to 10 weeks

Undiluted product: up to 31 days

Thawed, undiluted product can be transported at 2°C to 8°C for up to 12 hours but this counts against the 31-day limit.

Up to 30 days

Store at 2° to 8°C.

Expiry date found on vial label and refers to last day of that month.

Up to 6 months, not exceeding original expiry date (EXP).

Expiry date of vaccine should be checked and manually written on carton. See Product Monograph for additional details about expiry dates.

See here for EU English-only labelled product.

Dilution

Dilute thawed vials once they have reached room temperature with 1.3 mL of sterile 0.9% Sodium Chloride Injection, USP.

Dilute thawed vials once they have reached room temperature with 1.8 mL of sterile 0.9% Sodium Chloride Injection, USP.

Dilution/
reconstitution not required

Dilution/reconstitution not required Dilution/
reconstitution not required
Stability at Room Temperature (up to 25°C)

Prior to dilution, no more than 12 hours

After dilution, use within 12 hours from time of dilution.g  

(Time is additive: up to 24 hours at room temperature)

Prior to dilution, no more than 2 hours (including thaw time)

After dilution, use within 6 hours from time of dilution.

(Time is additive: up to 8 hours at room temperature)

Up to 24 hours 

Store in a refrigerator (2°C to 8°C). 

No stability data of unopened vial at room temperature. See stability after 1st puncture.  

Stable for a total of 12 hours at 9°C to 25°C
Stability after
1st Puncture
Up to 12 hours at 2°C to 25°C  Up to 6 hours at 2°C to 25°C 

Up to 24 hours  at 2°C to 25°C

Do not puncture and withdraw doses more than 20 times.h

Up to 6 hours at room temperature (up to 25°C)

Up to 48 hours when refrigerated (2°C to 8°C)

Product can be returned to the fridge but the cumulative time at room temperature must not exceed 6 hours and cumulative storage once opened must not exceed 48 hours.

Up to 3 hours at room temperature (up to 25°C)

Up to 6 hours at 2°C to 8°C

Protect from Light? Yes.
Store in original carton.
Yes.
Store in original carton.

Yes.
Store in original carton.

Yes.
Store in original carton.

Yes.
Store in original carton.

Handling

Invert gently during reconstitution.
Do not shake.

Invert gently during reconstitution.
Do not shake.

Swirl vial gently after thawing and between each withdrawal.
Do not shake.

None specified. Product is a solution.

Swirl gently upright for 10 seconds.
Do not shake.

Appearance

BEFORE dilution: thawed suspension may be white to off-white; may contain opaque amorphous particles.

AFTER dilution: white to off-white suspension; ensure no particulate matter/discolouration.

BEFORE dilution: thawed suspension may contain white to off-white opaque amorphous particles.

AFTER dilution: off-white suspension; ensure no particulate matter/ discolouration.

White to off-white dispersion—may contain white or translucent product-related particles; ensure no foreign particulate matter or discolouration.

Colourless to slightly brown, clear to slightly opaque solution; ensure no foreign particulate matter or discolouration.

Colourless to slightly yellow, clear to very opalescent suspension; ensure no foreign particulate matter or discolouration.

Clinical Information
Age Approved for individuals 5 to 11 years Approved for individuals 12 years and older Approved for individuals 12 years and older Approved for individuals 18 years of age and over Approved for individuals 18 years of age and older
Dosage for Primary Series 0.2 mL
(10 mcg mRNA)
0.3 mL
(30 mcg mRNA)
0.5 mL 
(100 mcg mRNA)

0.5 mL

 0.5 mL
Schedule # Doses to Complete Primary Series 2 2i 2i

2i,j

1k
Minimum Interval Between 1st and 2nd Doses 19 days per NACI 19 days per NACI based on per-protocol design of the trial 21 days per NACI based on the majority of participants in the trial received the 2nd dose 21 to 42 days after the 1st, as per the pre-defined window.

28 days

N/A
Authorized  Interval Between 1st and 2nd Doses

21 days 21 days 28 days

4 to 12 weeks

N/A
Ministry of Health Interval  Between 1st and 2nd Doses

21 days 28 days
(21 days is acceptable)
28 days 28 days N/A
Optimal Interval Between 1st and 2nd Doses per NACIl 8 weeks 8 weeks 8 weeks At least 8 weeks N/A
Booster Doses Find information about doses, eligibility and intervals here.
Route of Administration Intramuscular (deltoid preferred) Intramuscular (deltoid preferred) Intramuscular (deltoid preferred) Intramuscular (deltoid preferred) Intramuscular (deltoid preferred)

a. Packaging originally indicated 5 doses per vial though this has been updated to 6 doses per vial to minimize waste and increase access. Six doses can be achieved by using low dead-volume syringes and/or needles. If standard syringes and needles are used, there may not be sufficient volume to extract 6 full doses from a single vial.

b. Moderna Tx, Inc. is providing US-labelled vaccine supplies in order to expedite the distribution of the vaccine in Canada. The contents are identical to the Canadian-labelled product. However, important differences in packaging and labelling include:

  • Vials contain 8 mL providing 14 doses (US label maximum 15 doses) of 0.5 mL and are supplied in cartons of 10 vials
  • English-only labels
  • Important Canadian-specific information absent from labels (e.g. DIN)
  • Expiration dates are not printed on vial and carton labels

Continue to use the Canadian product monograph. For access to expiration dates, Canadian-specific labelling information and further details, see the Health Canada MedEffect notice.

c. On August 27, 2021, Health Canada expanded the Ultra Low Temperature storage conditions to now allow storage at -90°C to -60°C (-130°F to -76°F) versus the previously approved -80°C to -60°C (-112°F to -76°F). All references to storage conditions of -80°C to -60°C (-112°F to -76°F) on cartons and supporting printed material currently in Canada should now be considered between -90°C to -60°C (-130°F to -76°F.

d. On August 27, 2021, Health Canada authorized an update to the Pfizer-BioNTech Comirnaty™ Product Monograph to allow a 3-month extension to the expiry date for Pfizer-BioNTech Comirnaty™ ≥12 years product only (not pediatric product) vials with expiry dates of August 2021 through February 2022 printed on the vial and carton labels. Cartons and vials of Pfizer-BioNTech Comirnaty™ with an expiry date of August 2021 through February 2022 printed on the label may remain in use for 3 months beyond the printed date as long as all approved storage conditions have been maintained.

Printed Expiry Date Updated Expiry Date
August 2021 November 2021
September 2021 December 2021
October 2021 January 2022
November 2021 February 2022
December 2021 March 2022
January 2022 April 2022
February 2022 May 2022

e. Vials stored/transported at -25°C to -15°C for up to 2 weeks may be returned (once) to the recommended storage condition of -80°C to -60°C. Total time the vials are stored and /or transported at -25°C to -15°C should be tracked and not exceed 2 weeks.

f. Health Canada has authorized a 2-month shelf life extension (from 7 months to 9 months) for certain lots of the SPIKEVAX (previously COVID-19 Moderna vaccine). This extension applies to lots of US-labelled vaccine supplies with English-only vial and carton labels. See affected lots at the Health Canada Communication.

g. Vial labels and cartons may state that a vial should be discarded 6 hours after dilution; however, additional testing has been completed to support 12 hours of stability after dilution.

h. As per Health Canada Distribution of SPIKEVAX (elasomeran) COVID-19 Vaccine with English-only Vial and Carton Labels, Nov 10, 2021

i. See information about additional doses for moderately to severely immunocompromised individuals and recommendations for booster doses here

j.  Individuals who received two doses of AstraZeneca Vaxzevria™ as a primary series are eligible to receive an mRNA vaccine (Pfizer-BioNTech Comirnaty™ or Moderna Spikevax™) booster dose 5 months or later after completion of their primary series. AstraZeneca Vaxzevria™ (only available through Public Health) may be given to those for whom there is a contraindication to an mRNA vaccine.

k. Janssen (Johnson & Johnson) single dose vaccine recipients are eligible for a booster dose with an mRNA vaccine 2 months or later following their vaccination

l. There is emerging evidence that longer intervals between the first and second doses of COVID-19 vaccines result in more robust and durable immune response and higher vaccine effectiveness. Local transmission of the SARS-CoV-2 virus, the degree of individual risk of exposure to the virus, and the need of a second dose for earlier protection should be considered when deciding the interval. People who completed their primary vaccine series using manufacturer-authorized intervals also have very good protection against severe COVID-19 disease and do not need to restart their vaccine series.

References
Last updated

09 Dec 2021